Christoph Miethke

What Christoph Miethke does

Christoph Miethke GmbH & Co. KG is a privately held German medical technology company founded in 1992 and headquartered in Potsdam, Germany. The company specializes in implantable shunt systems for the treatment of hydrocephalus — a condition in which excess cerebrospinal fluid (CSF) accumulates in the brain's ventricles. MIETHKE's core technology centers on gravitational (anti-siphon) valves that automatically compensate for hydrostatic siphon effects when the patient is upright, addressing the overdrainage and underdrainage complications that plague conventional differential pressure shunts. The product portfolio spans adjustable valves (M.blue, M.blue plus, M.flow, proGAV 2.0, proGAV, proSA), preset valves (GAV 2.0, SA 2.0, GAV, paediGAV, SA, miniNAV, DSV), telemetric intracranial pressure sensors (M.scio, ICPicture), the THOMALE GUIDE surgical navigation instrument, antibiotic-impregnated catheters (XABO), reservoirs, and a digital application suite (MIETHKE App, HC&ME patient diary, THOMALE GUIDE app, Ventricle Guide training app, and the Produktfinder selection tool).

The business model is hardware-centric and centered on the sale of proprietary Class III implantable devices to hospital neurosurgical departments worldwide, with revenue driven by initial implantations and a recurring replacement cycle (the five-year shunt revision rate is approximately 40%). MIETHKE operates a field-sales motion targeting neurosurgeons and hospital procurement, complemented by a channel partnership with Aesculap AG (a B. Braun company) that handles regional distribution. The company maintains a strategic joint venture — B. Braun Miethke GmbH & Co. KG — focused on developing innovative drug delivery products. End-customers are highly fragmented across global neurosurgery departments; pricing is not publicly disclosed and is handled via sales representatives or the Aesculap channel. The company is founder-owned (led by Christoph Miethke as Founder and Managing Director alongside Daniel Rauch as co-Managing Director), with no external institutional or private equity backing identified. MIETHKE is recognized as one of the top five players in the global LP shunt market alongside Medtronic, Integra LifeSciences, SOPHYSA, and Hpbio, and competes in a broader VP shunt market projected to grow from $467M in 2025 to $745M by 2032.

Name

Christoph Miethke

Legal name

Christoph Miethke GmbH & Co. KG

Website

https://miethke.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

251–500 employees

Short description

Christoph Miethke GmbH & Co. KG is a German medical device company founded in 1992 that develops and manufactures hydrocephalus shunt systems, including gravitational and adjustable valves, telemetry intracranial pressure sensors, and antibiotic-impregnated catheters, selling to hospital neurosurgical departments worldwide.

Ownership category

akta.pro rank

Product category

Neurosurgical Implants - Hydrocephalus Shunt Systems

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)

akta.pro secondary industries

Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT) (HLAHADAG), Suction, Irrigation & Fluid Management Systems (HLAHADAK)

Keywords

• Hydrocephalus shunt systems
• Neurosurgical implant devices
• Adjustable pressure valves
• Intracranial pressure sensors
• CSF drainage management

Headquarters

HQ city

Potsdam

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Implantable Medical Device Sales: MIETHKE generates revenue through the sale of proprietary hydrocephalus shunt systems, valves, catheters, sensors, and instruments to hospitals and neurosurgical centers. The business is hardware-centric, with recurring replacement demand driven by a 40% five-year shunt revision rate.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Christoph Miethke GmbH & Co. KG designs, manufactures, and sells implantable hydrocephalus shunt systems, including adjustable and pre-set valves with proprietary gravitational (anti-siphon) assistance, antibiotic-impregnated catheters, telemetric intracranial pressure sensors, surgical instruments, and digital applications for neurosurgeons and hospital neurosurgical departments worldwide.

Product overview

Christoph Miethke GmbH & Co. KG is a medical technology company based in Potsdam, Germany, specializing in shunt systems for hydrocephalus treatment. The company offers a comprehensive portfolio centered around its core shunt valve technology with gravitational assistance. The product range includes adjustable valves (M.blue, M.blue plus, M.flow, proGAV 2.0, proGAV, proSA) that allow clinicians to modify opening pressures post-implantation, and pre-set valves (GAV 2.0, SA 2.0, GAV, paediGAV, SA, miniNAV, DSV) with fixed configurations. Supporting technologies include sensor technology products (M.scio telemetery ICP sensor, ICPicture) for intracranial pressure monitoring, surgical instruments (THOMALE GUIDE), and accessories such as the XABO antibiotic-impregnated catheter. Digital offerings include the MIETHKE App for clinicians, the HC&ME patient diary app, and the MIETHKE Produktfinder for product selection. The company operates as a joint venture with B. Braun (B. Braun Miethke GmbH & Co. KG) and focuses on gravity technology to address overdrainage complications in shunt therapy.

Differentiator

Problem solved

Functional benefit

Brands

• M.blue: Adjustable shunt valve for hydrocephalus treatment, available in standard and plus versions.
• proGAV 2.0
• proGAV
• proSA
• M.flow
• M.scio
• XABO

Products and services

• M.blue & M.blue plus Gravity-assisted adjustable differential pressure valve for hydrocephalus treatment, available in standard and plus versions with enhanced gravitational unit, used by neurosurgeons in adult hydrocephalus and iNPH therapy.
• M.flow Adjustable flow-regulating valve system for hydrocephalus management.
• proGAV 2.0 Programmable gravitational valve combining adjustable differential pressure technology with a gravitational unit for pediatric and adult hydrocephalus.
• proGAV Programmable adjustable differential pressure valve for hydrocephalus treatment.
• proSA Adjustable differential pressure valve with gravitational assist for hydrocephalus therapy.
• GAV 2.0 Gravity-assisted differential pressure valve with fixed opening pressure for hydrocephalus treatment.
• SA 2.0 Fixed-setting gravitational differential pressure valve for hydrocephalus.
• GAV Gravity-assisted differential pressure valve with pre-set opening pressure.
• paediGAV Pediatric-specific gravity-assisted differential pressure valve with fixed opening pressure.
• SA Gravitational differential pressure valve with pre-set configuration.
• miniNAV Compact pre-set differential pressure valve for hydrocephalus treatment.
• DSV Fixed-setting differential pressure shunt valve.
• M.scio Telemetric intracranial pressure sensor for long-term monitoring of hydrocephalus patients after shunt implantation, fully implantable with hermetically sealed metal housing.
• ICPicture Intracranial pressure measurement system providing visualization and monitoring of ICP data integrated with the MIETHKE product ecosystem.
• THOMALE GUIDE Surgical guidance instrument for precise shunt catheter placement during hydrocephalus surgery.
• XABO Antibiotic-impregnated catheter providing extra protection against infection in hydrocephalus therapy, reducing shunt infection rates to below 5%.
• MIETHKE App Mobile application for healthcare professionals to manage and adjust MIETHKE valve settings.
• HC&ME App Patient diary application enabling hydrocephalus patients to track symptoms and communicate with healthcare providers.
• MIETHKE Produktfinder Web-based product finder tool that filters relevant criteria based on patient situation, surgical technique, and treatment plan to recommend appropriate MIETHKE shunt products.

Quantifiable outcome

• Overdrainage avoided in approximately 1 in 3 patients with gravitational valves (SVASONA study)
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• B. Braun Miethke GmbH & Co. KG (Joint Venture)coreStrategic or Co-development PartnerB. Braun Miethke GmbH & Co. KG is a joint venture between Aesculap AG and Christoph Miethke (founder and CEO of Christoph Miethke GmbH & Co. KG), established with the goal of developing innovative drug delivery products. The joint venture operates at www.bbraun-miethke.com.
• Aesculap AGcoreChannel Partner/ Reseller/ DistributorAesculap AG (a B. Braun company) is a key channel partner and co-investor in the B. Braun Miethke joint venture. Aesculap handles regional distribution of MIETHKE products and receives product finder inquiries routed from miethke.com.
• University Hospital FrankfurtminorStrategic or Co-development PartnerClinical data from University Hospital Frankfurt demonstrated positive outcomes for LP shunt surgery using adjustable valve technology in treating idiopathic normal pressure hydrocephalus (iNPH), including reduced overdrainage complications.
• Korean clinical institutionsminorStrategic or Co-development PartnerClinical data from Korea demonstrated positive outcomes for LP shunt surgery in treating iNPH, supporting the efficacy of adjustable valve technology. These institutions provide clinical evidence for MIETHKE's technology.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Penumbra: Neurovascular and neurosurgery device specialist expanding into adjacent neuro indications. Comparable as a focused neuro-tech company with overlap in hospital neurosurgery buying channels and ICP-adjacent monitoring themes.
• Natus Medical: Specialty neurodiagnostics and neurosurgery device maker with adjacent ICP monitoring and neurology offerings. Comparable as a focused neuro-device player with partial product overlap in ICP monitoring technology.

Direct peers

• SOPHYSA: French manufacturer of hydrocephalus shunts and ICP monitoring devices. Direct competitor to MIETHKE in programmable/adjustable valves and intracranial pressure sensors.
• Medtronic: Dominant player in VP shunts and hydrocephalus management with global neurosurgery infrastructure. Direct competitor to MIETHKE in adjustable valves and CSF drainage, and one of the two anchors of the LP shunt market alongside Integra LifeSciences.
• Integra LifeSciences: Listed as one of the five key global LP shunt players (with MIETHKE, Medtronic, SOPHYSA, Hpbio). Competes directly in hydrocephalus shunts and neurosurgical implants through its Codman specialty neurosurgery portfolio.
• Hpbio: Korean hydrocephalus shunt manufacturer named alongside MIETHKE as one of the five global LP shunt key players. Competes directly in valve-based CSF management.

Broad incumbents

• B. Braun: Global medtech parent of Aesculap and JV partner with MIETHKE in B. Braun Miethke GmbH & Co. KG. Broadly comparable as a diversified incumbent investing in and distributing MIETHKE-adjacent neurosurgery and drug-delivery products.
• Codman Neuro (Johnson & Johnson MedTech): Historical leader in neurosurgical devices including shunts and external CSF drainage. Comparable as a broad incumbent in the same neurosurgery accounts with a portfolio approach to neuro critical care.
• Aesculap AG (B. Braun): Channel partner and JV counterparty in B. Braun Miethke; a much broader neurosurgery and surgical-instruments player within B. Braun. Comparable as a diversified incumbent overlapping MIETHKE's neurosurgery buyer base at much larger scale.
• Stryker (Neurosurgical / Spine): Large diversified medtech with significant neurosurgery/neuro-spine presence. Comparable as a broad incumbent overlapping MIETHKE's neurosurgery hospital buyers and procurement relationships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UC7iqSUOOhs0FOLVfYgHpOWg/featured
• LinkedInlinkedin.com/company/miethke
• Instagraminstagram.com/Miethke_international
• Xx.com/Miethke

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Christoph Miethke